Log in

NASDAQ:AKRXAkorn Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.23
-0.01 (-4.25 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.22
Now: $0.23▼
$0.25
50-Day Range
$0.09
MA: $0.19▼
$0.32
52-Week Range
$0.09
Now: $0.23▼
$5.46
Volume1.15 million shs
Average Volume9.60 million shs
Market Capitalization$30.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Read More
Akorn logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.59 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:AKRX
Previous Symbol
CUSIP00972810
CIK3116
Webwww.akorn.com
Phone847-279-6100

Debt

Debt-to-Equity Ratio0.09
Current Ratio0.50
Quick Ratio0.32

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$682.43 million
Price / Sales0.04
Cash Flow$1.19 per share
Price / Cash Flow0.19
Book Value$1.86 per share
Price / Book0.12

Profitability

EPS (Most Recent Fiscal Year)($0.34)
Net Income$-226,770,000.00
Net Margins-55.64%
Return on Equity8.53%
Return on Assets1.31%

Miscellaneous

Employees2,227
Outstanding Shares133,152,000
Market Cap$30.03 million
Next Earnings DateN/A
OptionableOptionable

Receive AKRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Akorn (NASDAQ:AKRX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Akorn?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Akorn.

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) issued its quarterly earnings results on Monday, May, 11th. The company reported $0.36 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.45. The business had revenue of $204.69 million for the quarter, compared to analyst estimates of $168.90 million. Akorn had a positive return on equity of 8.53% and a negative net margin of 55.64%.
View Akorn's earnings history.

What price target have analysts set for AKRX?

2 brokerages have issued 12 month price targets for Akorn's shares. Their forecasts range from $2.00 to $4.00. On average, they expect Akorn's stock price to reach $3.00 in the next year. This suggests a possible upside of 1,230.4% from the stock's current price.
View analysts' price targets for Akorn.

Has Akorn been receiving favorable news coverage?

Media coverage about AKRX stock has trended negative this week, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Akorn earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Akorn.

Who are some of Akorn's key competitors?

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).
View all competitors.

What other stocks do shareholders of Akorn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Who are Akorn's key executives?

Akorn's management team includes the following people:
  • Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
  • Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
  • Dr. Bruce Kutinsky, Consultant (Age 53)
  • Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)

What is Akorn's stock symbol?

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Who are Akorn's major shareholders?

Akorn's stock is owned by a variety of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.38%). Company insiders that own Akorn stock include Alan D Weinstein, Christopher Young, Jonathan Kafer, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn.
View institutional ownership trends for Akorn.

Which major investors are buying Akorn stock?

AKRX stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer, and Terry Allison Rappuhn.
View insider buying and selling activity for Akorn.

What is Akorn's stock price today?

One share of AKRX stock can currently be purchased for approximately $0.23.

How big of a company is Akorn?

Akorn has a market capitalization of $30.03 million and generates $682.43 million in revenue each year. The company earns $-226,770,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Akorn employs 2,227 workers across the globe.

What is Akorn's official website?

The official website for Akorn is www.akorn.com.

How can I contact Akorn?

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.